In one paragraphArticle in Cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
23 authors.
Riccardo BallaròDepartment of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-5505-9024 Truong LamDepartment of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-8634-8398 Sumedha PareekDepartment of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-6492-3849 Jonghae LeeDepartment of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-1182-9653 Hetal PatelDepartment of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0007-1669-9513 Priya TirumalaDepartment of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0005-3976-7713 Guanshu LiuDepartment of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0002-4556-2923 Karma HayekDepartment of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-6743-0027 Hannah SavageDepartment of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-4680-4656 Ryan De MalekiDepartment of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0006-1115-0129 Bella S GuerrouahenDepartment of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-4124-4389 An Ngo-HuangDepartment of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-4797-4147 Matthew H G KatzDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-3870-6968 Maria Q PetzelDepartment of Clinical Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-7982-8828 Florencia McAllisterDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-9915-0943 Robin D WrightDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-1317-8073 Retty A RoyDepartment of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0001-8459-6969 Ruben G AbrahamDepartment of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0006-4474-0870 Keyan PezeshkiDepartment of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0000-9198-927X Lin TanDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-5156-7814 Philip L LorenziDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-0385-7774 Keri L SchadlerDepartment of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-1675-0514 Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8MPancFit: Do angiogenic biomarkers correlate with improved progression free survival in pancreatic cancer?R21CA218732 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KATZ, MATTHEW H. G., NGO-HUANG, AN THUY · 2018 to 2019
$377kCancer Prevention and Research Institute of Texas (CPRIT) RP170067Cancer Prevention and Research Institute of Texas (CPRIT) RP190256Cancer Prevention and Research Institute of Texas (CPRIT) RP210028Mike Hogg FoundationNational Cancer Institute (NCI) 1R21CA218732-01A1National Cancer Institute (NCI) P30CA016672NCI NIH HHS P30 CA016672NCI NIH HHS R21 CA218732Pauline Altman-Goldstain Foundation Discovery FellowshipWyck Knox Family Fundation
6 · The paper itselfAbstract
Pancreatic ductal adenocarcinoma (PDAC) is characterized by high resistance to anticancer therapies, which is caused in part by hypovascularization and dysfunctional vessels that inefficiently deliver chemotherapy. Exercise has been shown to improve tumor vascular function and chemotherapy efficacy in preclinical models. Uncovering the mechanism by which exercise modifies tumor vasculature could help identify potential strategies to improve drug delivery. In this study, we evaluated surgically resected PDAC from patients who exercised during neoadjuvant chemotherapy to demonstrate that exercise remodeled PDAC vasculature and improved tumor vascular function in patients. In mice bearing orthotopic PDAC and treadmill exercise, tumor vascular remodeling was dependent on sphingosine-1-phosphate receptor 1 (S1PR1) signaling in endothelial cells, and S1PR1 was necessary for improved chemotherapy efficacy by exercise. Exercise activated S1PR1 in tumor endothelium, improved tumor vascular function, and increased gemcitabine (Gem) delivery and efficacy. Mice with an endothelial cell-specific S1PR1 deletion did not display exercise-induced improvements in tumor vascular function or Gem efficacy. These findings demonstrate that exercise increases chemotherapy delivery and efficacy by improving vascular function, defining S1PR1 as a necessary mediator of exercise-induced vascular remodeling. SIGNIFICANCE: Aerobic exercise induces tumor vasculature remodeling via endothelial S1PR1 to enhance drug delivery and suppress pancreatic cancer progression, supporting discovery of exercise efficacy biomarkers and therapeutic strategies for patients unable to exercise.
Indexed as
Carcinoma, Pancreatic DuctalEndothelial CellsNeovascularization, PathologicPancreatic NeoplasmsPhysical Conditioning, AnimalSphingosine-1-Phosphate ReceptorsAnimalsCell Line, TumorDeoxycytidineFemaleGemcitabineHumansMaleMiceSignal TransductionDeoxycytidineGemcitabineS1PR1 protein, humanSphingosine-1-Phosphate Receptors
Identifiers
PMID42314164
PMCPMC13383569
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390